Eledon Pharmaceuticals (Nasdaq: ELDN) announced several clinical development milestones for its investigational drug tegoprubart, an anti-CD40L antibody, across kidney and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE